SCHEMBL585377

SCHEMBL585377

FC(F)(F)c1ccc(Br)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.46
KDM1A O60341 2/20 0.42
NOTUM Q6P988 4/20 0.37
KMO O15229 2/20 0.37
DAO P14920 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HSD11B1 P28845 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
IDO1 P14902 1/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
KDR P35968 1/20 0.35
PDE2A O00408 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29589267 1.00 NT5E (0.46) NT5EKDM1ANOTUMKMODAO
SCHEMBL29268112 0.83 HSD11B1 (0.41) NT5EKDM1ANOTUMCYP3A4TSHR
SCHEMBL264729 0.82 IDO1 (0.47) NT5EKDM1ANOTUMIDO1HTR3E
SCHEMBL29707579 0.82 IDO1 (0.47) NT5EKDM1ANOTUMIDO1HTR3E
SCHEMBL27610724 0.80 IDO1 (0.46) NT5EKDM1ANOTUMIDO1HTR3E
SCHEMBL17943452 0.79 HSD11B1 (0.39) NT5EKDM1ANOTUMCYP3A4TSHR
SCHEMBL11553868 0.79 TSHR (0.60) NT5ECYP3A4TSHRMAPK1TDP1
SCHEMBL6267032 0.78 KDM1A (0.50) NT5EKDM1ANOTUMTSHRCYP11B1
SCHEMBL30864218 0.78 KDM1A (0.50) NT5EKDM1ANOTUMTSHRCYP11B1
SCHEMBL24252824 0.78 NT5E (0.37) NT5ENOTUMCYP3A4TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124197-A1 NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME HANMI PHARMACEUTICAL CO LTD (KR) 2026-05-07 US disclosed
EP-4729508-A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA Arcus Biosciences, Inc. (US) 2026-04-22 EP disclosed
EP-4426683-B1 BENZODIAZEPINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE GABA A GAMMA1 RECEPTOR HOFFMANN LA ROCHE (CH) 2026-04-01 EP disclosed
US-20260070912-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN-LA ROCHE INC. (US) 2026-03-12 US disclosed
US-20260008781-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN LA ROCHE (US) 2026-01-08 US disclosed
US-20260008782-A1 HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION CONVELO THERAPEUTICS, INC. 2026-01-08 US disclosed
US-20250388586-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN LA ROCHE (US) 2025-12-25 US disclosed
EP-4408848-B1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS HOFFMANN LA ROCHE (CH) 2025-11-05 EP disclosed
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-09 US disclosed
US-12404299-B2 Method for producing peptide compound comprising highly sterically hindered amino acid CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-02 US disclosed
EP-1805158-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR Kalypsys, Inc. (US) 2007-07-11 EP disclosed
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
US-20060205736-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC. 2006-09-14 US disclosed
US-20060167012-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC. 2006-07-27 US disclosed
WO-2006055187-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2006-05-26 WO disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed
EP-0109606-B1 PROCESS FOR THE FORMYLATION OF ARYL HALIDES BAYER AG (DE) 1986-01-22 EP disclosed
US-4536344-A USING A PHOSPINE OR PHOSPHITE BAYER AKTIENGESELLSCHAFT (DE) 1985-08-20 US disclosed
EP-0109606-A1 Process for the formylation of aryl halides BAYER AG (DE) 1984-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167012-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR PPARG, PPARA, PPARD NT5E 3872/4885KDM1A 3816/4885NOTUM 409/4885
US-20250388586-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM GABRA1, GABRB1, GABRA6 NT5E 4598/4885KDM1A 837/4885NOTUM 3874/4885
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS KRAS, HRAS, NRAS NT5E 4816/4885KDM1A 3675/4885NOTUM 4629/4885
US-20260124197-A1 NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME YAP1, RCC1, YES1 NT5E 4786/4885KDM1A 1765/4885NOTUM 3387/4885
US-20260008782-A1 HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION SGMS1, MAG, SGMS2 NT5E 4563/4885KDM1A 2298/4885NOTUM 2081/4885
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD NT5E 3841/4885KDM1A 3219/4885NOTUM 1475/4885
US-12404299-B2 Method for producing peptide compound comprising highly sterically hindered amino acid DNPEP, VIP, NPEPPS NT5E 1018/4885KDM1A 3930/4885NOTUM 1692/4885
US-20260008781-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM GABRA1, GABRA6, GABRB1 NT5E 4500/4885KDM1A 1033/4885NOTUM 3880/4885
US-20060205736-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR PPARG, PPARA, PPARD NT5E 3872/4885KDM1A 3816/4885NOTUM 409/4885
US-20260070912-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM GABRA1, GABRB1, GABRA6 NT5E 4663/4885KDM1A 808/4885NOTUM 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.